

## DAFTAR PUSTAKA

Alfonso, J. C. L. *et al.* (2020) 'On the Immunological Consequences of Conventionally Fractionated Radiotherapy', *iScience*. Elsevier, 23(3), p. 100897. doi: 10.1016/j.isci.2020.100897.

Alhmoud, J. F. *et al.* (2020) 'DNA damage/repair management in cancers', *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/cancers12041050.

Alix-Panabières, C. *et al.* (2012) 'Circulating Tumor Cells and Circulating Tumor DNA', *Annual Review of Medicine*, 63(1), pp. 199–215. doi: 10.1146/annurev-med-062310-094219.

Alix-Panabieres, C. and Pantel, K. (2014) 'Challenges in circulating tumour cell research', *Nature Review Cancer*, 14(9), pp. 623–631. doi: 10.1038/nrc3686.

Alix-Panabieres, C., Schwarzenbach, H. and Pantel, K. (2012) 'Circulating tumor cells and circulating tumor DNA', *Annu Rev Med*, 63, pp. 199–215. doi: 10.1146/annurev-med-062310-094219.

Andreopoulou, E. *et al.* (2012) 'Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system', *International Journal of Cancer*. Int J Cancer, 130(7), pp. 1590–1597. doi: 10.1002/ijc.26111.

Arneth, B. (2018) 'Update on the types and usage of liquid biopsies in the clinical setting: a systematic review', *BMC Cancer*. BMC Cancer, 18(1), p. 527. doi: 10.1186/s12885-018-4433-3.

Balic, M. *et al.* (2019) 'St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment', *Breast Care*. S. Karger AG, 14(2), pp. 103–110. doi: 10.1159/000499931.

Barnes, J. L. *et al.* (2018) 'Carcinogens and DNA damage', *Biochemical Society Transactions*. Portland Press Ltd, 46(5), p. 1213. doi: 10.1042/BST20180519.

Bourdeanu, L. and Liu, E. A. (2015) 'Systemic treatment for breast cancer: Chemotherapy and biotherapy agents', *Seminars in Oncology Nursing*, 31(2), pp. 156–162. doi: 10.1016/j.soncn.2015.02.003.

Boyle, S. T. and Kochetkova, M. (2014) 'Breast Cancer Stem Cells and the Immune System: Promotion, Evasion and Therapy', *Journal of Mammary Gland Biology and Neoplasia*, 19(2), pp. 203–211. doi: 10.1007/s10911-014-9323-y.

Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.', *CA: a cancer journal for clinicians*. doi: 10.3322/caac.21492.

Cabel, L. *et al.* (2017) 'Circulating tumor cells: clinical validity and utility', *International Journal of Clinical Oncology*. Springer Japan, 22(3), pp. 421–430. doi: 10.1007/s10147-017-1105-2.

Chaffer, C. L. and Weinberg, R. A. (2011) 'A perspective on cancer cell metastasis', *Science*, 331(6024), pp. 1559–1564. doi: 10.1126/science.1203543.

Chen, S. *et al.* (2019) 'In Vivo detection of circulating tumor cells in High-Risk Non-Metastatic Prostate Cancer Patients undergoing Radiotherapy', *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI), 11(7). doi: 10.3390/cancers11070933.

Coleman, M. P. *et al.* (2008) ‘Cancer survival in five continents: a worldwide population-based study (CONCORD)’, *The Lancet Oncology*. doi: 10.1016/S1470-2045(08)70179-7.

Darga, E. P. *et al.* (2021) ‘PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer’, *PLoS one*. PLoS One, 16(11). doi: 10.1371/JOURNAL.PONE.0260124.

Dasgupta, A., Lim, A. R. and Ghajar, C. M. (2017) ‘Circulating and disseminated tumor cells: harbingers or initiators of metastasis?’, *Molecular oncology*. Mol Oncol, pp. 40–61. doi: 10.1002/1878-0261.12022.

Deng, G. *et al.* (2008) ‘Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients’, *Breast Cancer Research*. Breast Cancer Res, 10(4). doi: 10.1186/bcr2131.

Dewan, M. Z. *et al.* (2009) ‘Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody’, *Clinical Cancer Research*. Clin Cancer Res, 15(17), pp. 5379–5388. doi: 10.1158/1078-0432.CCR-09-0265.

Diamond, J. M. *et al.* (2018) ‘Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs’, *Cancer Immunology Research*. Cancer Immunol Res, 6(8), pp. 910–920. doi: 10.1158/2326-6066.CIR-17-0581.

Dizdaroglu, M. (2012) ‘Oxidatively induced DNA damage: Mechanisms, repair and disease’, *Cancer Letters*, 327, pp. 26–47. doi: 10.1016/j.canlet.2012.01.016.

Drake, R. L., Vogl, A. W. and Mitchell, A. W. . (2019) *Gray’s Anatomy for Students, 4th Edition, Gray’s Anatomy for Students*.

Egner, J. R. (2010) ‘AJCC Cancer Staging Manual’, *JAMA*, 304(15), p. 1726. doi: 10.1001/jama.2010.1525.

Fernandez-Jimenez, N. *et al.* (2011) ‘Accuracy in copy number calling by qPCR and PRT: A matter of DNA’, *PLoS ONE*. PLOS, 6(12), p. 28910. doi: 10.1371/journal.pone.0028910.

Fields, E. C. *et al.* (2017) ‘Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future’, *Frontiers in Oncology*. Frontiers Media SA, 7, p. 177. doi: 10.3389/fonc.2017.00177.

Formenti, S. C. and Demaria, S. (2013) ‘Combining radiotherapy and cancer immunotherapy: a paradigm shift’, *Journal of the National Cancer Institute*. J Natl Cancer Inst, 105(4), pp. 256–265. doi: 10.1093/JNCI/DJS629.

Garrido-Navas, C. *et al.* (2019) ‘Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents’, *Cells 2019, Vol. 8, Page 1382*. Multidisciplinary Digital Publishing Institute, 8(11), p. 1382. doi: 10.3390/CELLS8111382.

Giuliano, A. E., Edge, S. B. and Hortobagyi, G. N. (2018) ‘Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer’, *Annals of Surgical Oncology*. Springer International Publishing, 25(7), pp. 1783–1785. doi: 10.1245/s10434-018-6486-6.

Gondhowiardjo, S. A. *et al.* (2020) ‘Tackling resistance to cancer immunotherapy: What do we know?’, *Molecules*. MDPI AG, p. 4096. doi: 10.3390/molecules25184096.

Gorges, T. M. *et al.* (2012) ‘Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition’, *BMC cancer*. BMC Cancer, 12. doi: 10.1186/1471-2407-12-178.

Hosseini, S. A. and Labilloy, A. (2020) 'Genetics, TREX1 Mutations', *StatPearls*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK544289/> (Accessed: 4 August 2021).

Hu, Y. *et al.* (2021) 'Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer', *Molecular Cancer Therapeutics*. Mol Cancer Ther, 20(12), pp. 2553–2567. doi: 10.1158/1535-7163.MCT-21-0195.

Ignatiadis, M., Georgoulas, V. and Mavroudis, D. (2008) 'Circulating tumor cells in breast cancer.', *Current opinion in obstetrics & gynecology*, 20(1), pp. 55–60. doi: 10.1097/GCO.0b013e3282f22b2e.

Jeong, H. *et al.* (2016) 'Radiation-induced immune responses: mechanisms and therapeutic perspectives', *Blood research*. Korean Society of Hematology, 51(3), p. 157. doi: 10.5045/BR.2016.51.3.157.

Jesenko, T. *et al.* (2020) 'Radiation induced upregulation of dna sensing pathways is cell-type dependent and can mediate the off-target effects', *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI), 12(11), pp. 1–23. doi: 10.3390/cancers12113365.

Jung, J. W. *et al.* (2007) 'Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells', *European Journal of Cancer*. doi: 10.1016/j.ejca.2007.01.034.

Juricic, P. and Ablasser, A. (2021) 'The spatial organization of cGAS-TREX1 interactions', *Developmental Cell*. Cell Press, 56(7), pp. 876–877. doi: 10.1016/j.devcel.2021.03.016.

Kalluri, R. and Weinberg, R. A. (2009) 'The basics of epithelial-mesenchymal transition', *Journal of Clinical Investigation*. American Society for Clinical Investigation, pp. 1420–1428. doi: 10.1172/JCI39104.

Kaur, P. and Asea, A. (2012) 'Radiation-induced effects and the immune system in cancer', *Frontiers in oncology*. Front Oncol, 2. doi: 10.3389/FONC.2012.00191.

Kavanagh, D. *et al.* (2008) 'New roles for the major human 3'-5' exonuclease TREX1 in human disease', *Cell Cycle*. Taylor and Francis Inc., 7(12), pp. 1718–1725. doi: 10.4161/cc.7.12.6162.

Koonce, N. A. *et al.* (2017) 'Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry', *Biochemical and Biophysical Research Communications*. Elsevier B.V., 492(3), pp. 507–512. doi: 10.1016/j.bbrc.2017.08.053.

Kozin, S. V. *et al.* (2010) 'Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation', *Cancer Research*. doi: 10.1158/0008-5472.CAN-09-4446.

Kuehn, T. *et al.* (2013) 'Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study', *The Lancet Oncology*. doi: 10.1016/S1470-2045(13)70166-9.

van Leeuwen, C. M. *et al.* (2018) 'The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies', *Radiation Oncology*. BioMed Central Ltd., pp. 1–11. doi: 10.1186/s13014-018-1040-z.

Li, N. *et al.* (2019) 'Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017', *Journal of Hematology & Oncology*. BioMed Central Ltd., 12(1), p. 140. doi: 10.1186/s13045-019-0828-0.

Lianidou, E. S. and Markou, A. (2011) 'Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges', *Clinical Chemistry*, pp. 1242–1255. doi: 10.1373/clinchem.2011.165068.

Liu, L. *et al.* (2020) 'Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review', *Radiation Oncology*. *Radiat Oncol*, 15(1), p. 17. doi: 10.1186/s13014-020-1463-1.

Magbanua, M. J. M. *et al.* (2022) 'Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy', *Frontiers in Oncology*. *Frontiers Media S.A.*, p. 607. doi: 10.3389/fonc.2022.802579.

Mannelli, C. (2019) 'Tissue vs Liquid Biopsies for Cancer Detection: Ethical Issues', *Journal of Bioethical Inquiry*. *J Bioeth Inq*, 16(4), pp. 551–557. doi: 10.1007/s11673-019-09944-y.

Martei, Y. M. *et al.* (2018) 'Breast Cancer in Low- and Middle-Income Countries', *Clinics in Laboratory Medicine*. *NIH Public Access*, 38(1), pp. 161–173. doi: 10.1016/j.cll.2017.10.013.

Martin, O. A. *et al.* (2014) 'Mobilization of Viable Tumor Cells Into the Circulation During Radiation Therapy', *International Journal of Radiation Oncology\*Biophysics\**, 88(2), pp. 395–403. doi: 10.1016/j.ijrobp.2013.10.033.

Massagué, J. and Obenauf, A. C. (2016) 'Metastatic colonization by circulating tumour cells', *Nature*. *Nature Publishing Group*, pp. 298–306. doi: 10.1038/nature17038.

Mattiuzzi, C. and Lippi, G. (2019) 'Current cancer epidemiology', *Journal of Epidemiology and Global Health*. *Atlantis Press International*, 9(4), pp. 217–222. doi: 10.2991/jegh.k.191008.001.

McDonald, E. S. *et al.* (2016) 'Clinical diagnosis and management of breast cancer', *Journal of Nuclear Medicine*. *Society of Nuclear Medicine Inc.*, 57, pp. 9S-16S. doi: 10.2967/jnumed.115.157834.

McGale, P. *et al.* (2014) 'Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials', *The Lancet*. doi: 10.1016/S0140-6736(14)60488-8.

Meng, S. *et al.* (2004) 'Circulating tumor cells in patients with breast cancer dormancy', *Clinical cancer research: an official journal of the American Association for Cancer Research*. *Clin Cancer Res*, 10(24), pp. 8152–8162. doi: 10.1158/1078-0432.CCR-04-1110.

Moo, T. A. *et al.* (2018) 'Overview of Breast Cancer Therapy', *PET Clinics*. *W.B. Saunders*, pp. 339–354. doi: 10.1016/j.cpet.2018.02.006.

Motwani, M., Pesiridis, S. and Fitzgerald, K. A. (2019) 'DNA sensing by the cGAS–STING pathway in health and disease', *Nature Reviews Genetics*. *Springer US*, 20(11), pp. 657–674. doi: 10.1038/s41576-019-0151-1.

Murphy, K. and Weaver, C. (2017) *Janeway's Immunology 9th Edition*, *America*.

N, B. *et al.* (2017) 'Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences', *Immunological reviews*. *Immunol Rev*, 280(1), pp. 249–279. doi: 10.1111/IMR.12573.

Nagao, T. *et al.* (2013) 'Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy.', *International journal of clinical oncology*, 18(1), pp. 54–61. doi: 10.1007/s10147-011-0343-y.

Pantel, K. and Speicher, M. R. (2016) 'The biology of circulating tumor cells', *Oncogene*. *Nature*

Publishing Group, 35(10), pp. 1216–1224. doi: 10.1038/onc.2015.192.

Parkes, E. E. *et al.* (2022) ‘Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer’, *British Journal of Cancer*. Nature Publishing Group, 126(2), pp. 247–258. doi: 10.1038/s41416-021-01599-0.

Perez, C. a. and Brady, L. W. (2011) ‘Radiation Oncology: Management Decisions’, p. 867. Available at: <http://books.google.com/books?id=-D9MbKnYcUAC&pgis=1>.

Rao, R. *et al.* (2013) ‘Axillary node interventions in breast cancer: A systematic review’, *JAMA - Journal of the American Medical Association*. doi: 10.1001/jama.2013.277804.

Rastogi, K. *et al.* (2018) ‘Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation’, *Radiation Oncology Journal*. doi: 10.3857/roj.2017.00381.

Reits, E. A. *et al.* (2006) ‘Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy’, 203(5). doi: 10.1084/JEM.20052494.

Rostas, J. W. and Dyess, D. L. (2012) ‘Current Operative Management of Breast Cancer: An Age of Smaller Resections and Bigger Cures’, *International Journal of Breast Cancer*. Hindawi Limited, 2012, pp. 1–7. doi: 10.1155/2012/516417.

Schindlbeck, C. *et al.* (2016) ‘Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets’, *Journal of Cancer Research and Clinical Oncology*. Springer Berlin Heidelberg, 142(9), pp. 1883–1895. doi: 10.1007/s00432-016-2118-3.

Schochter, F. *et al.* (2019) ‘Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions’, *Cells*. NLM (Medline). doi: 10.3390/cells8111412.

Scully, O. J. *et al.* (2012) ‘Breast cancer metastasis.’, *Cancer genomics & proteomics*, 9(5), pp. 311–20. doi: 9/5/311 [pii].

Shulman, L. N. *et al.* (2010) ‘Breast Cancer in Developing Countries: Opportunities for Improved Survival’, *Journal of Oncology*, 2010, pp. 1–6. doi: 10.1155/2010/595167.

Siva, S. *et al.* (2015) ‘Abscopal effects of radiation therapy: A clinical review for the radiobiologist’, *Cancer Letters*, 356(1), pp. 82–90. doi: 10.1016/j.canlet.2013.09.018.

SM, B. *et al.* (2008) ‘The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial’, *The Lancet*. Lancet, 371(9618), pp. 1098–1107. doi: 10.1016/S0140-6736(08)60348-7.

Sousa, C. *et al.* (2020) ‘Neoadjuvant radiotherapy in the approach of locally advanced breast cancer’, *ESMO Open*, 5(2), p. e000640. doi: 10.1136/esmopen-2019-000640.

Stott, S. L. *et al.* (2010) ‘Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.’, *Science translational medicine*, 2(25), p. 25ra23. doi: 10.1126/scitranslmed.3000403.

Svec, D. *et al.* (2015) ‘How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments’, *Biomolecular Detection and Quantification*. Elsevier, 3, pp. 9–16. doi: 10.1016/j.bdq.2015.01.005.

Tang, J. *et al.* (2021) 'Repurposing Radiation Therapy for Immuno-oncology', *Clinical Oncology*. Elsevier Ltd, 33(11), pp. 683–693. doi: 10.1016/j.clon.2021.08.015.

Tinganelli, W. and Durante, M. (2020) 'Tumor Hypoxia and Circulating Tumor Cells', *International Journal of Molecular Sciences*, 21(24), p. 9592. doi: 10.3390/ijms21249592.

Tohme, S., Simmons, R. L. and Tsung, A. (2017) 'Surgery for cancer: A trigger for metastases', *Cancer Research*. American Association for Cancer Research Inc., pp. 1548–1552. doi: 10.1158/0008-5472.CAN-16-1536.

Vanpouille-Box, C. *et al.* (2017) 'DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity', *Nature Communications*. Nature Publishing Group, 8(1), p. 15618. doi: 10.1038/ncomms15618.

Vanpouille-Box, C., Formenti, S. C. and Demaria, S. (2017) 'TREX1 dictates the immune fate of irradiated cancer cells', *OncImmunity*, 6(9). doi: 10.1080/2162402X.2017.1339857.

Vilalta, M. *et al.* (2014) 'Recruitment of Circulating Breast Cancer Cells Is Stimulated by Radiotherapy', *Cell Reports*. The Authors, 8(2), pp. 402–409. doi: 10.1016/j.celrep.2014.06.011.

Walker, R. *et al.* (2018) 'Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy', *Scientific Reports*, 8(1), p. 9474. doi: 10.1038/s41598-018-27718-1.

Wang, W.-C. C. *et al.* (2018) 'Survival Mechanisms and Influence Factors of Circulating Tumor Cells', *BioMed Research International*. Hindawi Limited, 2018, pp. 1–9. doi: 10.1155/2018/6304701.

Wang, W. C. *et al.* (2018) 'Survival mechanisms and influence factors of circulating tumor cells', *BioMed Research International*. Hindawi Limited. doi: 10.1155/2018/6304701.

Xing, Y. *et al.* (2006) 'Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.', *The British journal of surgery*, 93(5), pp. 539–546. doi: 10.1002/bjs.5209.

Yan, N. (2017) 'Immune diseases associated with TREX1 and STING dysfunction', *Journal of Interferon and Cytokine Research*. Mary Ann Liebert Inc., 37(5), pp. 198–206. doi: 10.1089/jir.2016.0086.

Yarmarkovich, M. *et al.* (2020) 'Immunogenicity and Immune Silence in Human Cancer', *Frontiers in Immunology*. Frontiers Media S.A., 11. doi: 10.3389/FIMMU.2020.00069.

Yarnold, J. (2018) 'Changes in radiotherapy fractionation—breast cancer', *The British Journal of Radiology*. Br J Radiol, 92(1093), p. 20170849. doi: 10.1259/bjr.20170849.

Yilmaz, M. T., Elmali, A. and Yazici, G. (2019) 'Abscopal Effect, From Myth to Reality: From Radiation Oncologists' Perspective', *Cureus*. Cureus, Inc., 11(1). doi: 10.7759/cureus.3860.

Zhang, X., Bai, X. and Chen, Z. J. (2020) 'Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway', *Immunity*. Immunity, 53(1), pp. 43–53. doi: 10.1016/j.immuni.2020.05.013.

Zhou, W. *et al.* (2021) 'cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing', *Molecular Cell*. Mol Cell, 81(4), pp. 739-755.e7. doi: 10.1016/j.molcel.2021.01.024.

